The Symphony of Profits: Why We Don't Cure the Golden Goose

 

The Symphony of Profits: Why We Don't Cure the Golden Goose

In the vast ecosystem of human endeavor, there is one rule that overrides even the survival of the species: the preservation of the business model. The story of Royal Raymond Rife and his 1934 "Frequency Cure" is often dismissed as a fever dream of the paranoid, but if we look at it through the cold lens of primate behavior, it makes perfect biological sense. In any troop, the "healer" holds power, but the "gatekeeper of the cure" holds the keys to the kingdom.

Rife’s supposed crime wasn't a lack of results; it was the sin of efficiency. According to the legend, his "Beam Ray Machine" used resonant frequencies to shatter cancer cells like a soprano shattering a wine glass—100% success, negligible cost. In the eyes of the burgeoning medical establishment of the 1930s, this was a catastrophic threat. You see, the human primate is a territorial creature that guards its food sources. By the mid-20th century, illness had become a primary food source for a massive, growing bureaucracy.

From a cynical business perspective, a "cure" is a market-ender. A "treatment," however, is a subscription service. If you kill the virus in an afternoon for $2,000, you lose a customer for life. If you manage the tumor over a decade with $150,000 rounds of chemotherapy, you have successfully "farmed" the patient. The destruction of Rife’s lab and the convenient "disappearance" of his clinical trials are simply the immune response of a $286 billion industry protecting its territory.

We like to believe we are rational beings driven by compassion, but history suggests we are still just clever apes who would rather burn a breakthrough to the ground than see it devalue our hoard of gold. The "MedBed" whispers of today are simply the ghost of Rife returning to haunt the balance sheets. Physics doesn't care about your profit margins, but the people who run the hospitals certainly do.